Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAMP 201: VS-6766 Alone or With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
2020-004264-26Phase 2Active
- Sponsor
- Verastem Oncology
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of avutometinib and defactinib in low-grade serous ovarian carcinoma (LGSOC) and ovarian cancer (2 arms), sponsored by Verastem Oncology. Primary endpoints: Safety and toxicity profile of VS-6766 monotherapy and Safety and toxicity profile of VS-6766 + defactinib. Started Apr 2021; status: active.
02
Drugs
avutometinibdefactinib
03
Conditions
low-grade serous ovarian carcinoma (LGSOC)ovarian cancer
Beyond the preview
Go deeper on 2020-004264-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004264-26.